Applied BioCode announced today that Beth Laderman has been appointed as their new Chief Scientific Officer signaling a significant step in the company’s expansion. With 25 years of experience in.
Further Broadens Reach of BioCode® MDx-3000 System into Hospitals and Reference Laboratories in the United States
U.S. Distribution of the Automated High Throughput Multiplex Molecular. | May 8, 2023
Hardy Diagnostics will begin offering Applied BioCode's MDx-3000 molecular diagnostic system, tests, and analyte specific reagents to US hospitals and reference laboratories.
QIAGEN launches the new LIAISON LymeDetect Assay based on QuantiFERON in partnership with DiaSorin selectscience.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from selectscience.net Daily Mail and Mail on Sunday newspapers.
Message :
Required fields DIASORIN, IN PARTNERSHIP WITH QIAGEN, LAUNCHES THE NEW LIAISON® LYMEDETECT® ASSAY BASED ON QUANTIFERON TECHNOLOGY IN COUNTRIES ACCEPTING CE MARK FOR EARLY DIAGNOSIS OF LYME BORRELIOSIS THE LIAISON® LYMEDETECT® ASSAY IS A SOLUTION FOR THE EARLY DIAGNOSIS OF LYME BORRELIOSIS COMBINING DETECTION OF IGG AND IGM ANTIBODIES AND CELLULAR IMMUNITY THE TEST IS AVAILABLE IN COUNTRIES ACCEPTING THE CE MARK AND IS DESIGNED TO BE RUN ON
THE LIAISON® XL AND LIAISON® XS PLATFORMS IN CLINICAL STUDIES, THE ASSAY SHOWED, WITHIN 21 DAYS FROM THE FIRST EVIDENCE OF INFECTION, A SENSITIVITY OF 74% VERSUS THAT OF EXISTING ESTABLISHED METHODS AT 49%, WHILE ALSO DEMONSTRATING A HIGH DIAGNOSTIC SPECIFICITY OF 100%